T2 BIOSYSTEMS INC (TTOO) Stock Price, Forecast & Analysis
NASDAQ:TTOO • US89853L3024
TTOO Key Statistics, Chart & Performance
The current stock price of TTOO is 0.134 USD. In the past month the price decreased by -58.13%. In the past year, price decreased by -97.54%.
TTOO Technical Analysis
TTOO Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TTOO. Both the profitability and financial health of TTOO have multiple concerns.
TTOO Financial Highlights
Over the last trailing twelve months TTOO reported a non-GAAP Earnings per Share(EPS) of -7.82. The EPS increased by 97.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -237.55% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TTOO Forecast & Estimates
6 analysts have analysed TTOO and the average price target is 5.1 USD. This implies a price increase of 3705.97% is expected in the next year compared to the current price of 0.134.
For the next year, analysts expect an EPS growth of 83.26% and a revenue growth 51.43% for TTOO
TTOO Ownership
TTOO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.94 | 402.079B | ||
| AMGN | AMGEN INC | 16.38 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 17.38 | 188.348B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.11 | 117.985B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.29 | 82.362B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.93 | 40.753B | ||
| INSM | INSMED INC | N/A | 31.174B | ||
| BIIB | BIOGEN INC | 12.92 | 28.692B | ||
| NTRA | NATERA INC | N/A | 28.683B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.07 | 20.502B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TTOO
Company Profile
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Company Info
T2 BIOSYSTEMS INC
101 Hartwell Ave
Lexington MASSACHUSETTS 02421 US
CEO: John Sperzel
Employees: 113
Phone: 17814571200
T2 BIOSYSTEMS INC / TTOO FAQ
Can you describe the business of T2 BIOSYSTEMS INC?
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 113 full-time employees. The company went IPO on 2014-08-07. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The firm's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. The company also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples.
Can you provide the latest stock price for T2 BIOSYSTEMS INC?
The current stock price of TTOO is 0.134 USD. The price decreased by -31.07% in the last trading session.
Does T2 BIOSYSTEMS INC pay dividends?
TTOO does not pay a dividend.
How is the ChartMill rating for T2 BIOSYSTEMS INC?
TTOO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for TTOO stock?
6 analysts have analysed TTOO and the average price target is 5.1 USD. This implies a price increase of 3705.97% is expected in the next year compared to the current price of 0.134.
How is the valuation of T2 BIOSYSTEMS INC (TTOO) based on its PE ratio?
T2 BIOSYSTEMS INC (TTOO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.82).
What is T2 BIOSYSTEMS INC worth?
T2 BIOSYSTEMS INC (TTOO) has a market capitalization of 3.76M USD. This makes TTOO a Nano Cap stock.